Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Highfine Biotech CoSZSE:301393 -6.28%91 Interest Coverage is 254.55 as of Jun. 2026, which is 53% below its 10-year median of 541.08. GuruFocus rates SZSE:301393 with a GF Score™ of 91/100 and a GF Value™ of ¥71.95 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 684 Drug Manufacturers companies, Suzhou Highfine Biotech Co ranks better than 82.75% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Suzhou Highfine Biotech Co's
Operating Income
for the
three
months ended in Jun. 2026 was ¥41.7 Mil. Suzhou Highfine Biotech Co's Interest Expense for the
three
months ended in Jun. 2026 was ¥-0.2 Mil.
Suzhou Highfine Biotech Co's interest coverage for the quarter that ended in Jun. 2026 was 254.55.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Suzhou Highfine Biotech Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Suzhou Highfine Biotech Co's Interest Coverage or its related term are showing as below:
SZSE:301393'
s Interest Coverage Range Over the Past 10 Years
Min: 145.27 Med: 541.08 Max: 1969.16
Current: 145.27
SZSE:301393's Interest Coverage is ranked better than 82.75% of 684
companies
in the Drug Manufacturers industry
Industry Median: 13.955
vs SZSE:301393: 145.27
Suzhou Highfine Biotech Co (SZSE:301393) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Suzhou Highfine Biotech Co Interest Coverage Related Terms
Suzhou Highfine Biotech Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Suzhou Highfine Biotech Co Interest Coverage Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Suzhou Highfine Biotech Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Highfine Biotech Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suzhou Highfine Biotech Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Suzhou Highfine Biotech Co's Interest Coverage falls into.
Suzhou Highfine Biotech Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Highfine Biotech Co (SZSE:301393) has a Interest Coverage of 254.55 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Suzhou Highfine Biotech Co and its competitors. This is 53% below median its historical median of 541.08. Over the past decade, Suzhou Highfine Biotech Co's Interest Coverage has ranged from 145.27 to 1,969.16. According to the industry distribution chart, Suzhou Highfine Biotech Co ranks #118 out of 684 companies in the Drug Manufacturers industry, placing it in the top 17.3%.
Is Suzhou Highfine Biotech Co's Interest Coverage too high?
Suzhou Highfine Biotech Co's current Interest Coverage of 254.55 is 53% below median its 10-year median of 541.08. Over the past 10 years, this metric has ranged from a low of 145.27 to a high of 1,969.16. The Drug Manufacturers industry median Interest Coverage is 13.96. Suzhou Highfine Biotech Co's value of 254.55 is 1724.1% above this industry median. Based on the distribution chart, Suzhou Highfine Biotech Co ranks #118 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Highfine Biotech Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Highfine Biotech Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suzhou Highfine Biotech Co ranks #118 out of 684 companies for Interest Coverage. This places Suzhou Highfine Biotech Co in the top 17% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.96. Suzhou Highfine Biotech Co's value of 254.55 is 1724.1% above this benchmark. Historically, Suzhou Highfine Biotech Co's own Interest Coverage has ranged from 145.27 to 1,969.16 over the past decade. While the company's 10-year median is 541.08 vs. the industry median of 13.96, Suzhou Highfine Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.96, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Highfine Biotech Co's current Interest Coverage of 254.55 is 1724.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Suzhou Highfine Biotech Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Highfine Biotech Co's current Interest Coverage is 254.55, which is 53% below median its own 10-year median of 541.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Highfine Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co (SZSE:301393) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥71.95, compared to a current price of ¥61.32 — trading 14.8% below its estimated fair value. The current Interest Coverage is 254.55, which is 53% below median its 10-year median of 541.08 and 1724.1% above the Drug Manufacturers industry median of 13.96. Suzhou Highfine Biotech Co's overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Suzhou Highfine Biotech Co (SZSE:301393), the current Interest Coverage is 254.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Highfine Biotech Co (SZSE:301393) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co stock appears to be undervalued.
The current stock price of ¥61.32 is trading 14.8% below its estimated GF Value™ of ¥71.95.
GuruFocus considers Suzhou Highfine Biotech Co to be Modestly Undervalued.
Key valuation signals for SZSE:301393:
Interest Coverage: 254.55 (53% below median its 10-year median of 541.08)
GF Value™: ¥71.95 vs. price of ¥61.32 (14.8% below fair value)
Industry Position: 1724.1% above the Drug Manufacturers median (#118 of 684)
No single metric tells the full story. See the SZSE:301393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.
91GF Score
Get the complete analysis for SZSE:301393
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301393 has been successfully added to your 
